Lonza Group


04/01/19 -"We have factored in more details for the divestment of the Water Treatment business and have made additional adjustments for 2018, 2019 and the following year. We have removed the extra income from ..."

Pages
53
Language
English
Published on
04/01/19
You may also be interested by these reports :
25/03/19
We have factored in our slightly more cautious view as we assume the investments for future growth in 2019 and the quick change at the CEO level will ...

22/03/19
Given the decreasing CellCept royalties and increasing proportion of low-margin product, Mircera, in the total sales mix, we lowered our profit ...

21/03/19
It is certainly not down to the market etiquette to compare Chemicals and Pharmas. Bayer (Reduce, Germany) bridges the two sectors however ...

20/03/19
Despite our lower EPS19, the target price moves slightly up driven by the higher earnings from 2020 onwards, and the higher DCF and SOTP valuations.

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO